The results from the CiPA Phase II multi-site, blinded validation study are now in. The CiPA team conclusively demonstrated the utility of human stem cell-derived cardiomyocytes to detect drug-induced arrhythmia effects. We are proud that the Maestro MEA system played a pivotal role in the study. We would also like to thank all the Maestro MEA users at big pharma for making us look great.
Learn more about CiPA Myocyte studies here.